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1 Drug description 
Generic/Brand name/ATC code: Lenalidomide/Revlimid®/ L04 AX04 
Developer/Company: Celgene Europe Limited 
Description: Lenalidomide is a second generation immune-modulatory 
agent with several modes of action, inducing anti-neoplastic, anti-
angiogenic, pro-erythropoietic and immune-modulatory effects. These 
effects are exerted by inhibition of TNF-α production, activation of T cells 
and by reduction of serum levels of the cytokines vascular endothelial 
growth factor and basic fibroblast growth factor [1, 2]. 
Revlimid® capsules are available at different dosages: 2.5 mg, 5 mg, 10 mg, 
15 mg and 25 mg. For myelodysplastic syndromes (MDS), the recommended 
daily dose is 10mg orally. It has to be noted though, that the optimal dosage 
has not been confirmed irrevocably since lower dosages have also shown ac-
tivity [3]. In addition  while the current recommendation is to administer 
lenalidomide until relapse of transfusion dependence, progression of disease 
or occurrence of intolerable side-effects [4], interruption of therapy 6 
months after complete cytogenetic remission might reduce costs and side-
effects while simultaneously achieving prolonged transfusion independence 
(TI) [4]. 
Due to the fact that neutropenia and thrombocytopenia are often the most 
serious side-effects of lenalidomide, complete blood counts should be per-
formed weekly for the first 8 weeks and monthly thereafter in MDS patients 
treated with this drug. Dose reductions or even interruption of treatment is 
necessary if neutropenia or thrombocytopenia develops. Other, serious ad-
verse events possible are deep venous thrombosis and pulmonary embolism, 
but if prophylactic use of anticoagulation or antiplatelet therapy is indicated 
has to be determined based on the individual patient’s medical record [5]. 
Special caution is required in females patients of childbearing age, because 
lenalidomide causes foetal harm at all doses [5]. 
2 Indication 
Lenalidomide for the treatment of red blood cell (RBC) transfusion-
dependent patients with low- or intermediate-1-risk MDS associated with a 
deletion 5q (del(5q)) cytogenetic abnormality.  
lenalidomide is  an 
immune-modulatory 
agent with anti-
neoplastic, anti-
angiogenic, pro-
erythropoietic effects 
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thrombocytopenia, deep 
venous thrombosis, 
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for low/intermediate 1 
risk MDS + del(5q) 
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3 Current regulatory status 
In Europe, lenalidomide is not licensed for the treatment of MDS, but the 
EMA granted market authorization for lenalidomide for  
 the treatment of multiple myeloma in 2007.  
Orphan drug designation was assigned for multiple myeloma in 2003, for 
myelodysplastic syndromes in 2004, for chronic lymphocytic leukaemia in 
2007, and for mantle cell lymphoma and diffuse large B-cell lymphoma in 
2011 [6].  
In the U.S., lenalidomide is an orphan drug, only available within the Re-
vAssist® Programme, a risk evaluation and mitigation strategy with the aims 
of informing on the serious risks and safe-use conditions for Revlimid® and 
to prevent the risk of foetal exposure to the drug. The Food and Drug Ad-
ministration (FDA) granted market authorisation for Revlimid® for [5]: 
 patients with transfusion-dependent anaemia due to low- or interme-
diate-1-risk MDS associated with a del(5q) abnormality with or with-
out additional cytogenetic abnormalities in December 2005.  
 multiple myeloma, in combination with dexamethasone, in patients 
who have received at least one prior therapy in June 2006.  
4 Burden of disease 
MDS are caused by genetic changes in haematopoietic precursor cells in the 
bone marrow. MDS might develop de-novo or as a secondary MDS after 
chemotherapy or radiation therapy for other diseases [7]. The inability of 
the bone marrow to produce mature blood cells results in cytopenia of one or 
more of the peripheral blood cells and in an increasing number of bone mar-
row blast cells – factors which relate directly to the prognosis [8]. Symptoms 
include anaemia - the most common cytopenia which occurs in more than 
90% of patients - repeated infections or bleeding [9]. About one third of pa-
tients suffering from MDS progress to acute myeloid leukaemia (AML)[8], 
which is often refractory to standard treatment [7].  
By reasons that MDS comprise a heterogeneous group of conditions, differ-
ent classification schemes mainly based on the cellular morphology are in 
use, such as the French-American-British Classification (FAB) or the WHO 
classification [7]. To assess the individual risk at diagnosis, the International 
Prognostic Scoring System (IPSS) discriminates four risk groups. Based on 
number of cytopenia, percentage of marrow blasts and karyotype (i.e. chro-
mosomal characteristics of a cell) different prognoses for survival and trans-
formation to AML can be made for each risk-group [8]. According to the 
IPSS, median survival (without therapy) ranges from 0.4 years to 5.7 years 
[10]. Patients in low or intermediate-1 risk category have an estimated me-
dian survival of 5.7 and 3.5 years respectively.  
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Depending on the type of chromosomal abnormalities, the IPSS differenti-
ates between “good”, “intermediate” and “poor” karyotypes. About 40-70% 
of patients show cytogenetic abnormalities, such as del(5q), -7 or del(7q), tri-
somy 8, del(20q), and loss of the Y chromosome [3]. Deletion of the long arm 
of chromosome 5 (del(5q)), the most common abnormality in MDS, is found 
in about 15% of patients. If there are no abnormalities, loss of the Y chromo-
some only or a del(5q) or del(20q) alone, the karyotype is rated as “good”. In 
contrast, complex abnormalities (i.e. ≥3) or chromosome 7 anomalies de-
termine poor karyotypes, whereas “intermediate” refers to all other abnor-
malities [8]. As reflected by the IPSS, MDS with del(5q) only have a relative 
good prognosis. If patients have an isolated del(5q) in addition to anaemia, 
normal or elevated platelet counts and fewer than 5% of blasts (i.e. imma-
ture precursor cells) in the bone marrow, this is referred to as 5q- syndrome 
[1, 8], a distinctive type of MDS mainly affecting older women (females vs 
males: 7:3) [3]. However, outcomes even of patients with del(5q) differ to a 
great extent. Additional chromosomal abnormalities seem to be  prognostic 
factors for risk of AML progression and overall survival, leading to three risk 
categories for AML transformation (del(5q), del(5q)+1 and del(5q)+ ≥ 2 
abnormalities) and two for OS (one group: del(5q) and del(5q)+1; and 
del(5q)+ ≥ 2 abnormalities, as the other one) [11]. Other factors which are 
discussed as being associated with an increased risk of AML transformation 
are a high risk WHO adapted Prognostic Scoring System score, a marrow 
blast count of >5% and red-blood cell transfusion dependency at diagnosis 
[12]. 
No data are available on the overall incidence of MDS in Austria, but esti-
mates from other countries range from 3.3 [13] to 5 per 100,000 people [14]. 
Applied to an Austrian population of 8,400,000 [15], an estimated 277 to 420 
persons would be affected. Assuming a frequency of del(5q) of 15%, ap-
proximately 40 - 60 patients are newly diagnosed in Austria each year. The 
median age of diagnosis is about 70 to 75 years [13] with 90% of patients 
aged over 60 at time of diagnosis. In individuals over 70 years the incidence 
rises to between 22 and  45 per 100,000 population [8]It is thus likely that 
this number will increase in the future due to the increasingly elderly stra-
tum of the population [16].  
5 Current treatment 
Asymptomatic patients with low-/intermediate-1-risk MDS do not require 
therapy, but should be monitored closely.  
For symptomatic patients, no standard therapy exists and enrolment in clin-
ical trials is highly recommended. Choice of therapy is influenced by pa-
tient’s performance status and disease characteristics such as cytopenias 
present, serum erythropoietin level and probability of responding to immu-
nosuppressive therapy.  
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Generally, treatment approaches for patients with low-/intermediate-1-risk 
MDS are supportive care and low intensity therapies, aiming at improving 
quality-of-life, reduction of symptoms caused by cytopenias and avoidance 
of toxic therapies.  
 Supportive care: including antibiotics, red blood and platelet transfu-
sions [3, 8] and iron chelation therapy (for patients which develop 
iron overload due to repeated blood cell transfusions).  
Supportive care is part of therapy for all MDS patients, but limiting 
therapy to supportive measures only, is indicated in frail older people 
with comorbidities [3, 17]. 
 Low intensity therapies: include the erythropoiesis stimulating agents 
(ESAs) erythropoietin or darbepoetin, growth factors (i.e. granulocyte 
colony stimulating factor (G-CSF)), DNA hypomethylating agents 
(i.e. azacitidine or decitabine) which are neither licensed nor recom-
mended for low-risk MDS in Austria [17], immunosuppressive ther-
apy (e.g. antithymocyte globulin and cyclosporine) for selected fit and 
younger patients and lenalidomide. 
 For patients with symptomatic anaemia, a serum erythropoietin 
level ≤500 mU/mL and without cytogenetic abnormalities, eryth-
ropoietin ± G-CSF is the preferred therapy. 
 Patients with symptomatic anaemia, with del(5q) ±other cytoge-
netic abnormalities and without clinically significant decreased 
neutrophils or platelets lenalidomide is considered as standard 
therapy, at least in the U.S. [3, 16-19].   
 Patients with symptomatic anaemia, a serum erythropoietin level 
>500 mU/mL, and a good probability of responding to immuno-
suppressive therapy (e.g. ≤60 years, hypocellular marrows), might 
be treated with antithymocyte globulin plus cyclosporine.  
 For patients with symptomatic anaemia, a serum erythropoietin 
level >500 mU/mL, who are unlikely to respond to immunosup-
pressive therapy and for patients with symptomatic thrombocyto-
penia or symptomatic neutropenia, hypomethylating agents and 
lenalidomide might be used [3, 17, 18].   
However, the majority of these regimens are considered as “ex-
perimental” and are not licensed for low/intermediate-1 risk MDS 
in Europe [17]. 
The only curative therapy for MDS is stem cell transplantation, a therapy 
which is, like intensive chemotherapy, usually restricted to patients with 
high-risk MDS.   
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LBI-HTA | 2012 7 
6 Evidence 
A literature search was conducted on the 17th of February in 4 databases (Ov-
id Medline, Embase, Cochrane Library, CRD Database) yielding 198 re-
sults. Considered were phase III and phase II studies, compassionate-use 
programmes and other relevant study designs which have been fully pub-
lished. Excluded were case-reports.  
Overall 8 references were included [20-27], comprising 1 phase III study 
[20], 1 phase II study with long-term results [21, 22], a compassionate use 
programme [23, 27], an open-label study [24], data from post-marketing sur-
veillance database [25] and a cost-effectiveness analysis [26]. 
 
8 references included  
1 phase III 
others: phase II, 
compassionate-use 
programme, post-
marketing surveillance 
data   
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6.1 Efficacy and safety - Phase III studies 
Table 1: Summary of efficacy 
Study title  
A randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del(5q) [20] 
Study  
identifier 
NCT00179621, CC-5013-MDS-004, 2005-000454-73 
Design Phase 3, multicentre (37 centres), randomized, double-blind, placebo-controlled 
Cross-over was allowed in the open label extension phase for patients in the lenalidomide 5 mg or in the placebo group 
 Duration  Enrolment: July 2005 to June 2007 
Median follow-up: 1.5 years 
Cut-off date for final analysis: June 2008  
Open-label extension phases: Patients without minor erythroid response by week 16 were discontinued from the double-blind 
phase, unblinded, and eligible for open-label treatment. Those completing the double-blind phase without disease progression or 
erythroid relapse were unblinded and could start open-label treatment at their current lenalidomide dose for up to 156 weeks. 
Hypothesis Superiority 
Assuming response rates (RBC-TI for 26 weeks) of 0.400 and 0.100 in the active and placebo groups, respectively, a sample size of 45 patients per group 
(mITT population) and a 2-group continuity corrected λ2 test with a 0.025 2-sided significance level (α split to adjust multiple comparisons) has an 80% 
power to detect differences between each active treatment group and placebo. 
Funding Celgene Corporation 
Treatment groups Intervention 1 
 
Randomised/mITT: n= 69/41 
lenalidomide 10 mg/day on days 1 to 21   
Duration: patients with at least a minor erythroid response (i.e. 50% decrease in transfusion requirements) by week 16 could 
continue double-blind treatment for up to 52 weeks or until erythroid relapse, disease progression, or unacceptable toxicity. 
Open-label therapy was offered for a maximum of 156 weeks to patients without disease progression or erythroid relapse. 
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 Intervention 2 Randomised/mITT: n= 69/47 
lenalidomide 5 mg/day on days 1 to 28 
Duration: patients with at least a minor erythroid response (i.e. 50% decrease in transfusion requirements) by week 16 could 
continue double-blind treatment for up to 52 weeks or until erythroid relapse, disease progression, or unacceptable toxicity. 
Open-label therapy was offered for a maximum of 156 weeks to patients without disease progression or erythroid relapse. Pa-
tients in the 5mg group without minor erythroid response by week 16 or those who had an erythroid relapse could-cross over to 
10mg open-label extension phase.  
 Control Randomised/mITT: n= 67/51 
placebo on days 1 to 28 
Duration: patients with at least a minor erythroid response (i.e. 50% decrease in transfusion requirements) by week 16 could 
continue double-blind treatment for up to 52 weeks or until erythroid relapse, disease progression, or unacceptable toxicity. Pa-
tients without minor erythroid response by week 16 or those who had an erythroid relapse could-cross over to 5mg or 10mg 
open-label extension phase. 
Endpoints and definitions Red blood cell transfu-
sion independence 
RBC-TI Red blood cell transfusion independence for ≥26 consecutive weeks 
 Erythroid response -  IWG 2000 criteria [9]: 
Response must last at least 8 weeks:  
Major response: for RBC transfusion-dependent patients, TI.  
Minor response: for RBC transfusion-dependent patients, 50% decrease in transfusion requirements. 
IWG 2006 criteria [28]: 
Response must last at least 8 weeks: For patients with pre-treatment haemoglobin less than 11 g/dL: Hgb increase by ≥ 
1.5 g/dL; relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 week 
compared with the pre-treatment transfusion number in the previous 8 wk. Only RBC transfusions given for a Hgb of ≤ 
9.0 g/dL pre-treatment will count in the RBC transfusion response evaluation. 
 Duration of RBC-TI  - Number of days between the last transfusion before the start of the TI period or the first dose of lenalidomide, which-
ever occurred later, and the first transfusion after the TI period (according to IWG 2000 criteria) 
 Cytogenetic response CR According to IWG 2000 criteria and determined based on karyotyping results [9]  
(requires 20 analysable metaphases using conventional cytogenetic techniques:  Major response: No detectable cyto-
genetic abnormality, if pre-existing abnormality was present. Minor response: 50% or more reduction in abnormal 
metaphases)  
 Overall survival  OS Time from randomization to death from any cause 
Time to acute myeloid 
leukaemia progression 
- Time from randomisation to diagnosis of AML (French-American-British criteria)  
Health-related quality 
of life 
HRQoL Assessed using the Functional Assessment of Cancer Therapy-Anaemia (FACT-An) questionnaire 
Horizon Scanning in Oncology 
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Results and analysis 
Analysis  
description 
Modified intent-to-treat (mITT) population was used to assess efficacy and included patients with centrally confirmed Low- or Intermediate-1-risk MDS 
with del(5q31) and documented RBC transfusion dependence, who received ≥ 1 dose of study drug. 
ITT population included randomised patients, safety analysis those who received ≥1 dose of study drug 
Analysis  
population 
Characteristics (mITT) Lenalidomide 10 mg Lenalidomide 5 mg Placebo 
Median age (range), years 68 (36-84) 66 (40 -86) 70 (39 -85) 
Females, % 68 79 80 
Transfusion burden, units/8 week (me-
dian, (range)) 
6 (2 -12) 7 (1 -25) 6 (4 -12) 
IPSS risk category (central review), % 
Low 
Intermediate 
 
49 
51 
 
40 
60 
 
57 
43 
WPSS risk category, % 
Very low 
Low 
Intermediate 
High 
Very high 
 
0 
5 
63 
32 
0 
 
0 
15 
49 
36 
0 
 
0 
4 
65 
29 
0 
FAB classification (central review), % 
RA 
RARS 
RAEB 
CMML 
Other or missing 
 
68 
20 
12 
0 
0 
 
68 
11 
15 
4 
2 
 
69 
16 
6 
2 
8 
  
EPO level, % 
≤500 mIU/mL 
>500 mIU/mL 
Missing 
Prior EPO use 
 
34 
51 
15 
59 
 
28 
51 
21 
51 
 
41 
47 
12 
47 
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Karyotype, % 
Isolated del(5q) 
Del(5q) ≥1 additional anomaly 
 
80 
20 
 
75 
25 
 
75 
25 
 Platelet count, % 
≥150 x109/L 
<150 x109/L 
25-50 x109/L 
 
81 
20 
2 
 
77 
23 
2 
 
84 
16 
0 
Inclu-
sion 
Patients 18 years of age or older with investigator-documented IPSS Low or Intermediate-1-risk MDS with del5q31, with or without additional 
cytogenetic abnormalities, and RBC transfusion-dependent anaemia (no 8 consecutive weeks without RBC transfusions within the 16 weeks be-
fore randomization) were included. Confirmation of del5q31 status (karyotype analysis) and bone marrow morphology was performed by cen-
tral hematologic review after randomization. 
Exclu-
sion 
Proliferative (white blood cell count ≥ 12 000/μL) chronic myelomonocytic leukaemia; grade≥2 neuropathy; prior use of lenalidomide; use of 
recombinant erythropoietin (EPO), chemotherapy, or treatment with any other investigational agent within the last 28 days or long-acting 
erythropoiesis stimulating agents within the last 8 weeks; and abnormal laboratory values (absolute neutrophil count <500/μL, platelet 
count<25 000/μL, serum creatinine>2.0 mg/dL, serum transaminases>3.0 x upper limit of normal [unless resulting from iron overload from 
blood transfusions], and serum total bilirubin>1.5 mg/dL) 
Descriptive statistics and es-
timated variability 
Treatment group Lenalidomide 10mg Lenalidomide 5 mg Placebo 
 mITT, n 41 47 51  
RBC-TI rates    
for ≥26 weeks during ≤52 
weeks, % (95%CI)  
56.1 (39.7 – 71.5) 
p<0.0011 
42.6 (28.3 – 57.8) 
p<0.0011 
5.9 (1.2 – 16.2) 
for ≥8 weeks using IWG 2000 
criteria during ≤52 weeks, % 
(95%CI)   
61.0 (44.5 – 75.8) 
p<0.0011 
51.1 (36.1 – 65.9) 
p<0.0011 
7.8 (2.2 – 18.9) 
 
for ≥8 weeks using IWG 2006 
criteria during ≤52 weeks, % 
(95%CI)   
61.0 (44.5 – 75.8) 
p<0.0011 
51.1 (36.1 – 65.9) 
p<0.0011 
5.9 (1.2 – 16.2) 
Duration of erythroid response     
Protocol defined erythroid re-
sponse (for ≥26 weeks), me-
dian in weeks (95%CI) 
NR NR NR 
                                                             
1 Versus placebo 
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IWG 2000-defined erythroid 
response (for ≥8 weeks), me-
dian in weeks (95%CI) 
NR (82.9 – NR) 
 
NR (41.3 – NR) - 
CR  rates, % 
Complete 
Partial 
Progression 
50.0 
29.4 
20.6 
23.5 
25.0 
15.6 
9.4 
31.3 
0; p<0.0011 
0 
0 
14.3 
ITT & safety population, n 69 69 67 
RBC-TI rates    
for ≥26 weeks during ≤52 
weeks, % (95%CI)  
55.1 (42.6 – 67.1) 
p<0.0011 
34.8 (23.7 – 47.2) 
p<0.0011 
6.0 (1.7 – 14.6) 
for ≥8 weeks using IWG 2000 
criteria during ≤52 weeks, % 
(95%CI)   
60.9 (48.4 – 72.4) 
p<0.0011 
47.8 (35.6 – 60.2) 
p<0.0011 
7.5 (2.5 – 16.6) 
for ≥8 weeks using IWG 2006 
criteria during ≤52 weeks, % 
(95%CI)   
60.9 (48.4 – 72.4) 
p<0.0011 
47.8 (35.6 – 60.2) 
p<0.0011 
6.0  (1.7– 14.6) 
OS, months 
median  
range 
 
44.5 
35.5 – NR 
  
≥35.5 
24.6 - NR 
 
42.4 
31.9 - NR 
AML Progression at 16 weeks, % 0 2.9 3.0 
FACT-An 
mean change from baseline at 
week 12 
 
5.8 
p<0.051 
 
5.9 
p<0.051 
 
-2.5 
Abbreviations: AML = acute myeloid leukaemia, ANC = absolute neutrophil count, CI = confidence interval, CMML = chronic myelomonocytic leukaemia; CR = cytogenetic response, dL = decili-
tre, EPO = erythropoietin, FAB = French-American-British, FACT-An = functional Assessment of Cancer Therapy-Anaemia, Hgb = haemoglobin, IWG = International Working Group, NR 
= not reached, mITT= modified intent-to-treat, mg = milligramme, mIU =milli-International Units, μL = microliter, mL = millilitre, OS = overall survival, RA = refractory anaemia, RAEB 
= RA with excess blasts, RARS = RA with ringed sideroblasts;  RCMD = refractory cytopenia with multi-lineage dysplasia, RBC = red blood cells, WPSS = World Health Organization classi-
fication-based Prognostic Scoring System, WHO = World Health Organization 
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Table 2: Grade 3 or 4 adverse events in ≥5% of patients (double-blind phase) 
Grade (ac-
cording to 
CTC 3.0) 
Outcome, n (%) Lenalidomide 10mg Lenalidomide 5mg Placebo 
Grade 3 or 4 Patients with ≥1 AE 65 (94) 62 (90) 29 (43) 
 Neutropenia 52 (75) 51 (74) 10 (15) 
 Thrombocytopenia 28 (41) 23 (33) 1 (2) 
 Leukopenia 6 (9) 9 (13) 0 
 Anaemia 2 (3) 4 (6) 6 (9) 
 Deep vein thrombosis 4 (6) 1 (1) 1 (2) 
Grade 5  Treatment-related death NA 1 (1%) NA 
Others AEs requiring dose  
reduction 
38 (55.1) 36 (52.2) NA 
 Dose interruption 32 (46.4) 20 (29.0) NA 
Abbreviations: NA = not available 
 
 
This phase III trial compared lenalidomide 5mg and 10mg to placebo. En-
rolled patients had to have investigator confirmed low/intermediate-1 risk 
MDS with del(5q31) with or without additional abnormalities and had RBC 
transfusion dependent anaemia (= 16 weeks prior to randomisation, there 
were no 8 weeks without RBC transfusions). These 205 patients randomised 
formed the intention to treat analysis (ITT). Red blood cell transfusion in-
dependence (RBC-TI), the primary endpoint was assessed for a modified 
ITT (mITT) population consisting of 139 patients with centrally confirmed 
low/intermediate-1-risk MDS. Thus, 59%-76% of patients from the initially 
randomised patients formed the mITT population. The mITT had a median 
age of 69 years, with the majority (68%-80%) being women. 6 units of RBC 
transfusions were required within 8 weeks. About 50% of all patients had 
been previously treated with erythropoetin, and about the same percentage 
had an erythropoeitin level >500mU/mL. An isolated del(5q31) was the 
most common cytogenetic abnormality (75%-81%) and platelet counts were 
within the physiological range in 77%-84%.  Concomitant use of G-CSF was 
allowed.  
These 205 patients, the ITT population, were randomised, initially to a dou-
ble-blind treatment phase. Individuals which showed at least a reduction of 
50% in transfusions required (=minor erythroid response) after 16 weeks, 
stayed in the double-blind phase for up to 52 weeks. Open-label phase ther-
apy was offered for a maximum of 156 weeks to patients without minor 
erythroid response by week 16, as well as to those which completed the dou-
ble-blind phase. In addition, patients initially assigned to either the placebo 
group or the lenalidomide 5mg group without minor erythroid response at 
16 weeks were allowed to cross-over to lenalidomide 5mg or 10mg in the 
open-label phase. Open-label therapy was not offered to patients whose dis-
ease progressed and to those with lenalidomide 10mg without minor 
erythroid response by week 16.  
phase III trial compared 
lenalidomide 10mg, 
lenalidomide 5mg and 
placebo 
205 patients overall = 
intention-to-treat 
population 
modified intention-to-
treat population:  
139 patients with 
centrally confirmed 
low/intermediate-1 risk 
MDS 
initially double-blind 
study, unblinding for 
patients without minor 
erythroid response 
cross-over was allowed 
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RBC-TI, the primary endpoint, had to last, as defined by the investigators, 
for at least 26 weeks and was achieved in 56% in the lenalidomide 10mg 
group and in 43% of the lenalidomide 5mg group in comparison to 6% in 
the placebo group of the mITT population. Similar results were found for 
RBC-TI as defined by the International Working Group criteria 2000 [9] 
and 2006 (i.e. RBC-TI for ≥8 weeks). Even though subgroup analyses for 
many characteristic had been performed, comparisons were only made be-
tween the two lenalidomide groups and not to placebo. However, besides le-
nalidomide therapy, higher platelet counts and longer time since diagnosis 
were identified as predictive factors for RBC-TI. Median duration of 
erythroid response was not reached yet in any of the lenalidomide groups.  
With a cytogenetic response rate of 50% and in 25% (more than half being 
complete responses) in the lenalidomide 10mg and 5mg groups, statistical 
significance was reached in comparison to the placebo group, where no cyto-
genetic response was observed.  
Health-related QoL was measured using the FACT-An score and showed 
better outcomes for both lenalidomide groups at 12 weeks and thus prior to 
cross-over. Short-term AML progression that is at 16 weeks was 3% in the 
placebo and in the lenalidomide 5mg group and 0% in the lenalidomide 
10mg group. Data for median OS are reported but are not meaningful due to 
cross-over.  
6% of patients had died within 30 days after last dose of placebo or 10mg 
lendalidomide in contrast to 3% in the 5mg group. The only death thought 
to be treatment-related was due to pulmonary embolism in the 5mg group.  
Adverse events (AE) of ≥3 were more frequent in the lenalidomide groups 
than in the placebo group, with one exception: anaemia was more often ob-
served in the placebo group. At least one AE grade≥3 occurred in 94%, 90% 
and in 43% in the lenalidomide 10mg, lenalidomide 5mg and in the placebo 
group respectively. Other AEs more common in the lenalidomide groups 
were neutropenia, thrombocytopenia and leukopenia, and deep vein throm-
bosis which was reported in 6% in the lenalidomide 10mg group (2% in the 
placebo group).  
Dose reductions were required in about 50% of patients treated with le-
nalidomide but no numbers were presented for the placebo arm. The most 
common reasons for lenalidomide dose reductions were neutropenia (10 mg, 
33%; 5 mg, 28%) and thrombocytopenia (10 mg, 22%; 5 mg, 12%). 
Dose interruption was reported in 46% and 29% in the lenalidomide 10 mg 
and 5 mg groups, respectively.  The most common reasons for lenalidomide 
dose interruptions were again neutropenia (10 mg, 23%; 5 mg, 12%) and 
thrombocytopenia (10 mg 13%; 5 mg 12%). 
6.2 Efficacy and safety - further studies 
A phase II study (MDS-003) enrolled 148 patients with low/intermediate-1 
risk MDS and del5q31 either alone or in addition to other cytogenetic ab-
normalities [21]. The vast majority of patients had an isolated del5q (74%), 
but some patients had also 5q syndrome (27%), del(5q) plus 1 additional ab-
normality (17%) or had even complex (≥3) abnormalities (8%) [29]. This 
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study, published in 2006, served as basis for the FDA’s decision for market 
licensing in the U.S.  
Enrolled patients had transfusion-dependent anaemia and were treated with 
10mg lenalidomide which was initially given for 21 consecutive days in a 28 
day cycle (in 46 patients), but dosing was changed to daily administration 
later on (in overall 102 patients). Previous therapeutic regimens included 
erythropoietin (73%), chemotherapy (39%) and iron-chelation therapy 
(37%). RBC-TI, the primary outcome, was defined as the absence of any 
RBC transfusion during any consecutive “rolling” 56 days (8 weeks) during 
the treatment period was achieved in both dosing schedules in 99 patients 
(=67%), showing no relevant difference between the two groups. An addi-
tional 13 patients (=9%) required at least 50% fewer transfusions. Response 
to lenalidomide therapy occurred rapidly (median 4.6 weeks). Haemoglobin 
levels rose in patients with TI by 5.4 g/dl and median peak haemoglobin 
concentration in these patients was 13.4 g/dl. 53 patients (=53% of TI indi-
viduals) remained transfusion independent for at least 1 year at a median 
follow-up of 104 weeks. Rates of TI were investigated according to specific 
clinical as well as pathological features, showing only a significant difference 
for platelet counts and transfusion need prior to therapy. If platelet counts 
were ≥100,000/μl 73% of individuals treated achieved TI in contrast to 39% 
of patients with <100,000/μl. Similarly, better outcomes were seen for pa-
tients who required <4 units/8 weeks RCT. Of 85 evaluable patients, 45% 
had a complete cytogenetic response which was defined as the absence of 
cells in metaphase containing any abnormal clone at 24 weeks; 28% had a 
partial response. This outcome was independent of karyotype complexity. 
Estimated median OS was 7.6 years for patients with del(5q) only and 5.6 
years for patients with more than one abnormality at a median follow-up of 
3.8 years. Progression to AML occurred in 8 out of 106 patients.  
In terms of AEs, neutropenia (grade ≥3: 55%) and thrombocytopenia (grade 
≥3: 44%) were the most common ones and occurred within the first eight 
weeks of therapy. 11 patients died, of which 3, that is 2%, believed as treat-
ment-related were attributed to neutropenic infection. Dose adjustments 
were necessary in 84% and 20% stopped lenalidomide therapy due to AEs. 
Göhring et al. present long-term follow-up data from all European patients 
enrolled at the MDS-003 study [22]. At a median follow-up of 3.3 years, 
overall 42 patients were included of which 6 were assigned after the closure 
of the MDS-003 trial. 29% achieved a continuous TI and the same percent-
age achieved a transient TI. Initially 48%, that is 20 patients, had a cytoge-
netic response but it remains unclear if these were complete or partial re-
sponses. During follow-up, 12 of these patients lost cytogenetic responses. At 
a median time of 51 months, 36% had progressed to AML of which all but 
one patient died. The authors also analysed relationship of several factors 
such as age, gender or IPSS risk score to AML progression and found differ-
ences for patients with or without erythroid/cytogenetic responses. Patients 
with erythroid/cytogenetic responses had a significantly decreased risk of 
AML progression at three (10%) and five years (21%) than non-responders 
at three years: 46%, at five years: 60%. During progression to AML, most of 
the clones with del(5q) acquired additional chromosome aberrations and de-
veloped into complex clones. Thus, genetic instability and clonal evolution 
seem to be the driving forces of leukaemic transformation in MDS patients 
treated with lenalidomide. Even though patients with responses progressed 
more rarely to AML than those without responses, the small sample size lim-
ited significance of these findings. 
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A compassionate use programme, conducted in France, comprised 95 pa-
tients with low risk MDS with del(5q) [23]. Of these, the majority had iso-
lated del(5q) (79%) whereas the rest had 1 (14%) or more than 1 additional 
(6%) abnormality. Treatment consisted of 10mg lenalidomide daily for 21 
days every 28 days for at least 16 weeks. TI was achieved in 65% of patients 
and platelet count at baseline or a platelet decrease by ≥50% was again the 
only factors associated with prediction of TI. During follow-up (median 18 
months) 6 patients (6%) progressed to AML. Higher grade AEs were similar 
to those reported in the previous studies, since the most common ones were 
thrombocytopenia (40%) and neutropenia (74%), side effects which caused 
three deaths. 10% developed venous thromboembolism and dose reductions 
or treatment discontinuation due to AEs were reported for 48%. Another 
publication compared these patients to a historical control group of 99 pa-
tients with lower risk MDS with del(5q) who were never treated with le-
nalidomide [27]. After controlling for potential confounders (due to the non-
randomised control), 71 matched patients were found in both groups. For 
these, the estimated cumulative incidence of AML from diagnosis was 9% in 
the lenalidomide group and 16% in the control group, yielding no signifi-
cant difference. Also, OS was similar in the two groups (p=0.06).  
An open-label study enrolled 11 Japanese patients with low risk MDS with a 
del(5q) abnormality [24]. 5 had transfusion dependent anaemia and 6 were 
TI but had symptomatic anaemia. Treatment consisted of 10mg lenalido-
mide in a 28 day cycle. All 5 patients achieved TI and haemoglobin levels 
rose from 7.1 to 12.7g/dL, but improvements in haemoglobin levels were al-
so found for patients with TI. Grade ≥3 AEs were neutropenia (91%), leu-
kopenia (55%), lymphopenia (27%) and thrombocytopenia (9%). A total of 8 
(73%) patients had lenalidomide dosages reduced from 10 mg daily to 5 mg 
daily (21 consecutive days). Furthermore, administration was temporarily 
interrupted in 8 (73%) patients due to AEs. The reason for the dose reduc-
tion as well as for dose interruption was grade ≥3 neutropenia. 
Yang et al. [25] investigated occurrence of venous thromboembolism (i.e. 
deep vein thrombosis and pulmonary embolism) in 7,764 MDS patients with 
lenalidomide exposure between December 2005 and December 2007 which 
had been identified by the RevAssist®, the restrictive distribution pro-
gramme in the U.S. Information on cases of venous thromboembolism was 
obtained from the company’s post-marketing surveillance safety database. 
For calculation of disproportional signal scores, a technique which allow as-
sessment of associations between drug exposure and occurrence of side-
effects but not of causal relationships, a commercial version of FDA’ Ad-
verse Event Reporting System database was used. Since risk group and cyto-
genetic abnormalities were not routinely collected, these characteristics 
could not be specified. To test if concurrent administration of ESAs in-
creased the risk of venous thromboembolism, three different categories were 
formed: patients with lenalidomide but without ESA, patients with ESA in 
the absence of lenalidomide and patients exposed to both lenalidomide and 
ESA. Only if lenalidomide and ESAs were administered concurrently, a sta-
tistically association was found, but not if lenalidomide only was used. Re-
ported rates of venous thromboembolism were 0.53%.  
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Goss et al. [26] conducted a cost-effectiveness analysis of lenalidomide 
(10mg) and best supportive care without erythropoietin in comparison to 
best supportive care (BSC) with erythropoietin. This study, which was spon-
sored by the manufacturer, calculated the costs for an American setting 
based on the rate and duration of TI as assessed in the MDS-003 trial [21] in 
comparison to patients from the “Nordic MDS Group” trials and the pla-
cebo controlled arm of a phase III-MDS trial.  When costs of medications, 
transfusions, chelation, laboratory test, office visits and other resources were 
calculated for the outcomes measures TI and quality-adjusted life-years, le-
nalidomide yielded an incremental 0.53 transfusion-free and 0.25 QALYs 
compared to BSC at 1 year. Total treatment costs, also at 1 year, were $ 
63,400 for lenalidomide and $ 54,900 for BSC. These numbers results in an 
incremental cost-effectiveness ratio of $ 16,000 per transfusion-free year and 
in $ 35,000 per QALY gained and were thus considered as cost-effective for 
the American setting.  
7 Estimated costs 
In Austria, the costs for one package 10mg lenalidomide containing 21 tab-
lets for the labelled indication are € 5,475 [30]. Without any required dose 
reductions or interruptions this would be the costs for one 28 days cycle.  
Savings might incur due to fewer transfusions required and hence a less fre-
quent use of hospital services. Moreover, transfusion dependent patients 
with del(5q) treated with supportive care alone will shortly accumulate iron 
overload and should receive due to their potentially benign clinical course 
iron chelation treatment. Older MDS patients are mostly not candidates for 
intravenous infusions of iron chelation therapy and receive therefore oral 
therapy at considerable costs. Achieving TI thus prevents accumulation of 
iron overload and saves the cost of iron chelation therapy. On the other 
hand, additional therapy with G-CSF factors might be indicated and hospi-
tal admissions for the treatment of AEs might increase.  
8 On-going research 
On www.clinicaltrials.gov 3 on-going phase III studies for the investigated 
indication were found: 
NCT01243476: a phase III multi-centre, randomized, double blind, placebo 
controlled trial and with two arms designed to assess the efficiency and tox-
icity of the scheme lenalidomide versus observation in a series of 60 patients 
with low risk MDS associated to 5q deletion with anaemia (Hb≤12g/dL) but 
without the need of transfusion. Estimated study completion date is January 
2016.  
NCT00843882: a randomized phase III trial studying lenalidomide to see 
how well it works with or without epoetin α in treating patients with MDS 
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and anaemia, sponsored by the National Cancer Institute. The estimated 
Study Completion Date was September 2009, yet no results are available.  
NCT01029262: The purpose of this study is to investigate whether lenalido-
mide would reduce the number of RBC transfusions needed by anaemic 
(RBC transfusion-dependent) subjects with low or intermediate-1 risk MDS 
without a deletion 5q chromosome abnormality. The study will also investi-
gate the safety of lenalidomide use in these subjects. Two-thirds of the sub-
jects will receive lenalidomide and one-third of the subjects will receive pla-
cebo (does not contain lenalidomide). Estimated study completion date is 
December 2017. 
On www.clinicaltrialsregister.eu no phase III trial was found for MDS.  
9 Commentary  
In the U.S., lenalidomide was licensed in 2005 for patients with transfusion-
dependent anaemia due to low- or intermediate-1-risk MDS associated with 
a del(5q) abnormality with or without additional cytogenetic abnormalities 
[24]. The MDS-003 trial [31], a single-arm phase II study, formed the basis 
for the FDA’s decision. Even though the FDA’s Oncologic Drugs Advisory 
Committee expressed concerns that a single-arm trial does not allow proper 
assessment of lenalidomide’s safety profile, a favourable benefit-risk profile 
was confirmed [32]. The EMA, on the other hand, has not granted market 
authorisation for this indication, because of lack of comparative data for the 
risk of AML progression [16, 33]. However, the drug is already used in Aus-
tria [34]. 
In May 2012, the FDA released a safety announcement, notifying the public 
that patients with newly diagnosed multiple myeloma which had been treat-
ed with lenalidomide had almost a three-fold increased risk of developing 
new types of cancer, especially AML, MDS and B-cell lymphoma malignan-
cies [35]. A pooled analysis of three RCTs showed second primary malig-
nancies in 7.9% in the lenalidomide group in comparison to 2.8% (p<0.001) 
in the groups which had not received lenalidomide. Healthcare professionals 
are thus advised to weigh this risk against the potential benefits of the drug 
when considering initiation of Revlimid® therapy. In Europe, EMA’s Com-
mittee for Medicinal Products for Human Use concluded that efficacy gains 
such as an improved overall survival justify the associated risks despite a 
four-fold increase in the number of new cancers (solid tumours and cancers 
of the blood and the immune system) in patients treated with lenalidomide 
for multiple myeloma, which is the licensed indication in Europe [36].  
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Therapy of low/intermediate-1 risk MDS aims at improving cytopenia asso-
ciated symptoms. The treatment of anaemia, the most frequent cytopenia, 
increases quality-of-life and extends survival by reducing risk of heart-
failure [37]. Lenalidomide was investigated in patients with 
low/intermediate-1-risk MDS and with del(5q), but it remains unclear 
which additional features, besides del(5q), patients have to show. Some au-
thors suggest that lenalidomide can be used in patients with thrombocyto-
penia/neutropenia [3], whereas others point out that patients with a low 
platelet/neutrophil count were excluded from both the phase III study and 
the phase II study [8]. Moreover, erythropoietin treatment failure [19, 37]  or 
serum erythropoietin level >500 mU/mL [3] are discussed as prerequisites 
for treatment initiation. In contrast, some evidence suggests that response to 
erythropoetin is lower in patients with del(5q) MDS than in other, low-risk 
MDS [38]. Also, further gene mutations might determine prognosis and thus 
choice of therapy [8] as, for example, evidence suggests that non-responders 
to lenalidomide may have an increased risk of developing chromosomal ab-
normalities and have consequently a higher risk of AML progression [22]. 
Therefore, patients should be monitored for cytogenetic response by using 
both fluorescence in situ hybridization and karyotyping to determine if and 
when treatment should be initiated and stopped [39]. 
The two studies, mentioned above, included to a great extent similar pa-
tients which are representative for the target population [20, 31]: more wom-
en were enrolled, median age was about 70 years and the majority of patients 
did not have thrombocytopenia; more than 75% of patients had an isolated 
del(5q). More patients had received prior erythropoetin therapy (73%) in the 
study by List et al. [31] than in the RCT (52%) [20] but the median number 
of RBC transfusions in the 8 weeks before the studies’ start was 6 in both tri-
als. RBC-TI for ≥26 weeks was achieved in 56% of patients treated with le-
nalidomide 10mg in comparison to 6% in the placebo group. In the uncon-
trolled trial TI for ≥56 days was observed in 67% overall. Complete and par-
tial response rates for the 10mg group was 29% and 21% and 0% for the pla-
cebo group. The phase II study showed a complete response in 45% and a 
partial response in 28%. Due to cross-over at 16 weeks, longer-term results 
for AML progression from the phase III are difficult to interpret. Only 11 
patients (out of 67) had never received lenalidomide. Of these 4 (i.e. 36%) 
progressed. Of patients allocated to the lenalidomide 10mg group, 22% pro-
gressed to AML. In the phase II study, corresponding numbers were 8%.  
In terms of AEs, myelosuppression occurring early in the treatment course 
was the most frequent one. In the placebo-controlled trial, grade ≥3 throm-
bocytopenia and neutropenia was observed in 41% and 75% in the 10mg 
group and in 2% and 15% in the placebo group during the double-blind 
treatment phase. Any AE grade ≥3 was seen in 94% of patients treated with 
10mg in contrast to 43% of patients treated with placebo. In the lenalido-
mide groups, dose reductions were necessary in about 50% and treatment in-
terruption was reported in 46% (10mg group) and 29% (5mg group) [20]. 
Rates of deep vein thrombosis were 6% [20] and 3% in the two groups [31]. 
A subgroup analysis of the phase II study population conducted by the spon-
sor and confirmed by the FDA, revealed that AEs occurred twice as often in 
patients aged over 65 years [32]. No such information is provided for the 
phase III study but would be of high interest, since MDS patients are usu-
ally diagnosed with 70 years.  
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Therapeutic options for patients with low/intermediate-1 risk MDS are 
transfusion of RBC and erythropoietic growth factors ± G-CSF [37]; for pa-
tients with del(5q) lenalidomide offers an alternative. Despite improved 
(short-term) outcomes for patients treated with lenalidomide in comparison 
to placebo, the impact on OS remains unclear. However, RBC-TI clearly of-
fers advantages for patients because time consuming hospital visits for re-
peated RBC transfusions are replaced by an oral drug [38]. This also implies 
that, at least in Austria, costs would be shifted from hospitals to the social 
health insurance. Nonetheless, potential savings due to a reduced number of 
hospital admissions for RBC transfusion and reduced need of costly iron 
chelation therapies might be outweighed by admissions for the treatment of 
AEs and by the rather expensive drug itself. However, estimating overall 
costs for lenalidomide is difficult, since the optimal treatment duration as 
well as the dosage remain unclear, because evidence indicates that interrup-
tion of lenalidomide therapy 6 months after complete cytogenetic remission 
rather than continuation until disease progression may achieve prolonged 
TI, a fact which would reduce costs [4].   
Another question concerns occurrence of secondary malignancies and pro-
gression to AML. The latter one was assessed in the phase III study, but me-
dian time to progression was not reached in the lenalidomide groups and re-
sults are compromised due to cross-over. Some evidence from registries and 
retrospective analyses, published more or less by the same group of authors,  
indicates that the risk of AML progression and occurrence of second pri-
mary malignancies are not increased by lenalidomide therapy [27, 40, 41]. 
The same authors also retrospectively compared outcomes of patients <65 
years to patients ≥65 years whom had been included in the phase III study 
and in the MDS-004 trial (published as abstract only) [42]. Even though 
they found similar rates of RBC-TI ≥ 26 weeks, younger patients achieved 
cytogenetic remissions less often and more patients progressed to AML. 
However, long-term outcomes from direct comparisons between lenalido-
mide treated and untreated patients are needed to ultimately judge these 
risks. 
It seems as patients can benefit from lenalidomide at the expenses of severe 
AEs and potential secondary cancers. Thus further refinement of criteria for 
patient selection (e.g. number of chromosomal abnormalities or transfusion 
need at diagnosis), close observation with dose reductions/interruptions if 
necessary and follow-up investigations to identify non-responders are basic 
prerequisites to avoid exposure to lenalidomide therapy and potential sec-
ondary tumours of patients which do not benefit from this therapy.   
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